Evidence map›Paper›PMID 33764002›Full record

ArticleHaematologica2021

Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma.

Heli Vajavaara, Frida Ekeblad, Harald Holte, Judit Jorgensen, Suvi-Katri Leivonen, Mattias Berglund, Peter Kamper, Holger J Moller, Francesco D'Amore, Daniel Molin and 4 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Heli VajavaaraResearch Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.
Frida EkebladExperimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
Harald HolteDepartment of Oncology and KG Jebsen center for B-cell malignancies, Oslo University Hospital, Oslo.
Judit JorgensenDepartment of Hematology, Aarhus University Hospital, Aarhus.
Suvi-Katri LeivonenResearch Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.
Mattias BerglundExperimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
Peter KamperDepartment of Hematology, Aarhus University Hospital, Aarhus.
Holger J MollerDepartment of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus.
Francesco D'AmoreDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus.
Daniel MolinExperimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
Gunilla EnbladExperimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
Maja LudvigsenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus.
Ingrid GlimeliusExperimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Medicine, division of clinical epidemiology, Karolinska Institutet, Solna. Ingrid.glimelius@igp.uu.se.
Sirpa LeppaResearch Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki. sirpa.leppa@helsinki.fi.
Uppsala University · SEAarhus University Hospital · DKUniversity of Helsinki · FIAarhus University · DKHelsinki University Hospital · FIOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, CDLymphoma, Large B-Cell, DiffuseAntigens, Differentiation, MyelomonocyticAntineoplastic Combined Chemotherapy ProtocolsCD163 AntigenHumansPrognosisReceptors, Cell SurfaceAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenReceptors, Cell Surface

Identifiers

PMID33764002
PMCPMC8409034
OpenAlexW3137472566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.